AAAAAA

   
Results: 1-8 |
Results: 8
A phase I study of CNI-1493, an inhibitor of cytokine release, in combination with high-desk interleukin-2 in patients with renal cancer and melanoma
Authors: Atkins, HB Redman, B Mier, J Gollob, J Weber, J Sosman, J MacPherson, BL Plasse, T
Citation: Hb. Atkins et al., A phase I study of CNI-1493, an inhibitor of cytokine release, in combination with high-desk interleukin-2 in patients with renal cancer and melanoma, CLIN CANC R, 7(3), 2001, pp. 486-492
Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer
Authors: Hussain, M Vaishampayan, U Du, W Redman, B Smith, DC
Citation: M. Hussain et al., Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer, J CL ONCOL, 19(9), 2001, pp. 2527-2533
Immunological effects of BCG as an adjuvant in autologous tumor vaccines
Authors: Li, Q Normolle, DP Sayre, DM Zeng, XY Sun, R Jiang, GH Redman, B Chang, AE
Citation: Q. Li et al., Immunological effects of BCG as an adjuvant in autologous tumor vaccines, CLIN IMMUNO, 94(1), 2000, pp. 64-72
Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions
Authors: Trask, PC Esper, P Riba, M Redman, B
Citation: Pc. Trask et al., Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions, J CL ONCOL, 18(11), 2000, pp. 2316-2326
Management of melanoma with a multidisciplinary melanoma clinic model
Authors: Johnson, TM Chang, A Redman, B Rees, R Bradford, C Riba, M Lowe, L
Citation: Tm. Johnson et al., Management of melanoma with a multidisciplinary melanoma clinic model, J AM ACAD D, 42(5), 2000, pp. 820-826
Weekly 1-hour infusion of paclitaxel: clinical feasibility and efficacy inpatients with hormone-refractory prostate carcinoma. (vol 89, pg 431, 2000)
Authors: Trivedi, C Redman, B Flaherty, LE Kucuk, O Wei, D Heilbrun, LK
Citation: C. Trivedi et al., Weekly 1-hour infusion of paclitaxel: clinical feasibility and efficacy inpatients with hormone-refractory prostate carcinoma. (vol 89, pg 431, 2000), CANCER, 89(6), 2000, pp. 1412-1412
Weekly 1-hour infusion of paclitaxel - Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma
Authors: Trivedi, C Redman, B Flaherty, LE Kucuk, O Du, W Heilbrun, LK Hussain, M
Citation: C. Trivedi et al., Weekly 1-hour infusion of paclitaxel - Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma, CANCER, 89(2), 2000, pp. 431-436
Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer
Authors: Smith, DC Esper, P Strawderman, M Redman, B Pienta, KJ
Citation: Dc. Smith et al., Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer, J CL ONCOL, 17(6), 1999, pp. 1664-1671
Risultati: 1-8 |